Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of REGN2222 (suptavumab) for Prevention of Medically Attended RSV Infection in Preterm Infants
2015-001714-96Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing REGN2222 (suptavumab) with Placebo (2 arms). Started Aug 2015; status: completed.
02
Drugs
suptavumab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2015-001714-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001714-96.